Synaptojanin-1 Antibody #80377
- WB
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 173 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro1186 of human Synaptojanin-1 protein. Antibodies are purified by peptide affinity chromatography.
Background
Synaptojanin-1 is a nerve terminal-enriched phosphatase that dephosphorylates phosphoinositides (1-3). Synaptojanin-1 contains an N-terminal Sac1 PI4P phosphatase domain (Sac domain) that dephosphorylates PI3P and PI(3,5)P2, a central 5-phosphatase domain that dephosphorylates PI(4,5)P2 and PI(3,4,5)P3, and an RNA recognition motif (4). In the brain, synaptic vesicles are released in response to action potentials, releasing neurotransmitters from synaptic vesicles and initiating interneuronal communication. As part of the synaptic vesicle cycle, fused synaptic vesicle membranes and proteins are endocytosed to be recycled to generate new synaptic vesicles in order to maintain neuronal function. A complex set of proteins, enriched in synaptic vesicles and synaptic membrane, via interaction with highly regulated lipid compositions at the synapse, dynamically regulate the synaptic vesicle cycling process (5). As part of that machinery, Synaptojanin-1 initiates completion of synaptic vesicle endocytosis by regulating, with its partner endophilin-A, the removal of clathrin and the formation of the vesicle “neck” (6). The dephosphorylation of PI(4,5)P2 at the synaptic membrane by Synaptojanin-1 phosphatase activity is critical in shedding endocytic factors from their membranes (4,7). Recently, several genetic studies have linked proteins that participate in synaptic vesicle endocytic recycling, including Synaptojanin-1, to early onset Parkinson's disease (4).
- McPherson, P.S. et al. (1996) Nature 379, 353-7.
- Chung, J.K. et al. (1997) J Biol Chem 272, 15980-5.
- Chang-Ileto, B. et al. (2011) Dev Cell 20, 206-18.
- Cao, M. et al. (2017) Neuron 93, 882-896.e5.
- Sudhof, T.C. (2004) Annu Rev Neurosci 27, 509-47.
- Watanabe, S. et al. (2018) Neuron 98, 1184-1197.e6.
- Mani, M. et al. (2007) Neuron 56, 1004-18.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.